-
Product Insights
Respiratory Syncytial Virus (RSV) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Respiratory syncytial virus (RSV) infection infects the lungs and breathing passages. RSV commonly causes bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children less than one year of age. The Respiratory Syncytial Virus pipeline market research report provides comprehensive information on the therapeutics under development for Respiratory Syncytial Virus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological...
-
Product Insights
Asthma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Asthma, a chronic disease involving the airways in the lungs, may occur with symptoms that include shortness of breath, chest tightness or pain, chronic coughing and trouble sleeping due to coughing or wheezing. The Asthma pipeline drugs market research report outlays comprehensive information on the Asthma targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type, that are being developed by companies/universities. It also reviews key players involved in...
-
Product Insights
Neisseria Meningitidis Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neisseria meningitidis Infections – Drugs In Development, 2022, provides an overview of the Neisseria meningitidis Infections (Infectious Disease) pipeline landscape. Neisseria Meningitidis is a severe bacterial infection of the bloodstream and meninges (a thin lining covering the brain and spinal cord). Symptoms include fever, neck stiffness, joint pain, nausea, confusion and drowsiness. Risk factors include age, smoking, mucosal lesions, overcrowding, climatic conditions such as dry seasons or prolonged drought and...
-
Track & Monitor
Coronavirus Disease (COVID-19) Impact on Biopharmaceutical Venture Capital Deals
This report examines the impact of the COVID-19 pandemic on venture capital deals for biopharmaceutical companies. This analysis is critical to understanding how the outbreak of COVID-19 impacted investments and how those VC deal trends may impact current and future venture capital investments.